Nancy Lurker joined EyePoint Pharmaceuticals (f/k/a pSivida) in September 2016 as President and Chief Executive Officer and is a member of the company’s Board of Directors. Ms. Lurker has more than 30 years’ experience in the pharmaceutical and pharmaceutical services industries. Prior to joining EyePoint, Ms. Lurker was President and CEO at PDI a leading commercialization and contract sales company that commercialized hundreds of pharmaceutical drugs, devices, OTC and diagnostic tests in collaboration with their business partners through PDI’s 1100 sales representatives. In 2015, Nancy led the sale of PDI’s contract sales division to Publicis Touchpoint Solutions. Prior to joining PDI, she was SVP and Chief Marketing Officer for Novartis Pharmaceuticals Corporation where she oversaw a $6 billion product portfolio in multiple therapeutic areas. Ms. Lurker was also President and CEO of ImpactRx, a private equity-backed market research firm servicing the biopharmaceutical industry. Prior to ImpactRx she was Group VP – Global Primary Care Products for Pharmacia Corporation, and a member of Pharmacia’s US Executive Management Committee. She began her career at Bristol Myers Squibb, where she quickly rose from Senior Medical Representative to Senior Director of Worldwide Cardiovascular Franchise Management where she many successful drug launches. Ms. Lurker graduated magna cum laude with a BS in biology from Seattle Pacific University, and holds an MBA from the University of Evansville (Evansville, IN). Nancy also serves on the Board of Cancer Treatment Centers of America and Aquestive Therapeutics and is a member of the Novo Advisory Group.